Review
Ipilimumab: a promising immunotherapy for melanoma
Affiliations
- PMID: 21294471
Item in Clipboard
Review
Ipilimumab: a promising immunotherapy for melanoma
Oncology (Williston Park).
2010 Dec.
Free article
Abstract
Antibody-based targeting of the immune suppressor molecule cytotoxic T-lymphocyte antigen 4 (CTLA-4) with ipilimumab has been studied in metastatic melanoma in a number of clinical trials, including a recent phase III trial. This marks the first randomized clinical trial reporting an overall survival benefit using immune modulation in metastatic melanoma. Along with its therapeutic benefits, ipilimumab presents unique challenges to clinicians; these are related to the monitoring of treatment response and the management of drug-related toxicities. This drug is currently being investigated in various cancers, and its indications are likely to be expanded.
Comment in
-
Improving the therapeutic benefits of ipilimumab.Oncology (Williston Park). 2010 Dec;24(14):1288, 1294. Oncology (Williston Park). 2010. PMID: 21294472 No abstract available.
-
Ipilimumab for advanced melanoma: let's not throw caution to the winds.Oncology (Williston Park). 2010 Dec;24(14):1296, 1299. Oncology (Williston Park). 2010. PMID: 21294473 No abstract available.
-
CTLA-4-blocking immunotherapy with ipilimumab for advanced melanoma.Oncology (Williston Park). 2010 Dec;24(14):1302, 1304. Oncology (Williston Park). 2010. PMID: 21294474 No abstract available.
Similar articles
-
Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).Oncologist. 2008;13 Suppl 4:16-25. doi: 10.1634/theoncologist.13-S4-16. Oncologist. 2008. PMID: 19001147 Review.
-
Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy.Semin Oncol. 2010 Oct;37(5):533-46. doi: 10.1053/j.seminoncol.2010.09.015. Semin Oncol. 2010. PMID: 21074069 Review.
-
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Semin Oncol. 2010. PMID: 21074058 Review.
-
Ipilimumab for advanced melanoma: a nursing perspective.Oncol Nurs Forum. 2009 Jan;36(1):97-104. doi: 10.1188/09.ONF.97-104. Oncol Nurs Forum. 2009. PMID: 19136343 Review.
-
Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.Transl Res. 2015 Nov;166(5):412-24. doi: 10.1016/j.trsl.2015.06.005. Epub 2015 Jun 11. Transl Res. 2015. PMID: 26118951 Free PMC article. Review.
Cited by
-
Evolving Immunotherapy Approaches for Renal Cell Carcinoma.Curr Oncol Rep. 2016 Sep;18(9):57. doi: 10.1007/s11912-016-0542-9. Curr Oncol Rep. 2016. PMID: 27475806 Review.
-
Plasma Cells in the Melanoma Tumor Microenvironment-Mechanistic Roles for IgA.Front Immunol. 2020 Jun 5;11:979. doi: 10.3389/fimmu.2020.00979. eCollection 2020. Front Immunol. 2020. PMID: 32582154 Free PMC article. No abstract available.
-
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?Dermatol Res Pract. 2012;2012:182157. doi: 10.1155/2012/182157. Epub 2011 Oct 23. Dermatol Res Pract. 2012. PMID: 22046181 Free PMC article.
-
CD8+ CD122+ regulatory T cells contain clonally expanded cells with identical CDR3 sequences of the T-cell receptor β-chain.Immunology. 2013 Jul;139(3):309-17. doi: 10.1111/imm.12067. Immunology. 2013. PMID: 23317140 Free PMC article.
-
Integrative Bioinformatics Analysis for Targeting Hub Genes in Hepatocellular Carcinoma Treatment.Curr Genomics. 2025;26(1):48-80. doi: 10.2174/0113892029308243240709073945. Epub 2024 Jul 18. Curr Genomics. 2025. PMID: 39911278 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
